Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
Condition(s) studied
Investigational drug(s) / intervention(s)
Budesonide: Twice daily intake of the tablet 30 min after a meal
Study summary
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
Eligibility
Primary outcome measure(s)
- Proportion of patients in histological remission — 6 weeks
Histological assessment of biopsies taken at end of treatment visit
Trial sites (21)
| Facility | City | Region | Status |
|---|---|---|---|
| Dr. Falk Investigational Site | Scottsdale | Arizona | |
| Dr. Falk Investigational Site | Little Rock | Arkansas | |
| Dr. Falk Investigational Site | La Jolla | California | |
| Dr. Falk Investigational Site | San Diego | California | |
| Dr. Falk Investigational Site | Doral | Florida | |
| Dr. Falk Investigational Site | New Port Richey | Florida | |
| Dr. Falk Investigational Site | Boise | Idaho | |
| Dr. Falk Investigational Site | Boston | Massachusetts | |
| Wyoming | Ann Arbor | Michigan | |
| Dr. Falk Investigational Site | Wyoming | Michigan | |
| Dr. Falk Investigational Site | Rochester | Minnesota | |
| Dr. Falk Investigational Site | Freehold | New Jersey | |
| Dr. Falk Investigational Site | New York | New York | |
| Dr. Falk Investigational Site | Chapel Hill | North Carolina | |
| Dr. Falk Investigational Site | Cleveland | Ohio | |
| Dr. Falk Investigational Site | Mentor | Ohio | |
| Wyoming | Philadelphia | Pennsylvania | |
| Dr. Falk Investigational Site | Harlingen | Texas | |
| Dr. Falk Investigational Site | Salt Lake City | Utah | |
| Dr. Falk Investigational Site | Lynchburg | Virginia | |
| Department of Gastroenterology, Hospital General de Tomelloso | Tomelloso | Spain |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06596252 on ClinicalTrials.gov ↗ ← All trials in Spain